Featured XIENCE short DAPT trials
XIENCE – Protecting Patients with Short DAPT Needs
In the late breaking STOPDAPT2 trial1, a 3000-patient RCT, 1-month DAPT demonstrated superior safety over 12-month DAPT in the primary endpoint – Net Adverse Cardiovascular Events (NACE) – (cardiovascular death, MI, Def ST, Stroke, or TIMI major/minor bleeding) in patients treated with XIENCE. XIENCE, is supported by the largest and most comprehensive body of evidence for short DAPT, with over 19,000 patients2 analyzed.
Primary non-inferiority analysis at 12 months. Secondary superiority analysis at 60 months.
Learn more about STOPDAPT 2 at:https://clinicaltrials.gov/ct2/show/NCT02619760?term=stopdapt2&rank=1*NACE is a composite of CV death, Ml, ST, Stroke. TIM I major/minor bleeding (Net Clinical Benefit)
Abbott has established the XIENCE Short DAPT program of clinical trials, which focuses on high risk bleeding patients. Shortening DAPT (Dual AntiPlatelet Therapy) duration may be particularly important for patients at higher risk of bleeding, e.g., older patients, patients taking anticoagulants, and patients with anemia or renal disease.
The studies in the XIENCE Short DAPT program are:
Dr. Mehran is global principal investigator of the XIENCE 90 trial. The principal investigator of the XIENCE 28 study is Marco Valgimigli, MD.
Currently physicians have no clear guidance when weighing their patients’ needs and risk factors—their need for DAPT to reduce ischemic complications after percutaneous coronary intervention (PCI) and, for many patients, their bleeding risk while on prolonged DAPT.
“We have a lot of patients in whom DAPT cannot be longer than 1 [month] and we need to provide some answers to them.”
— MARCO VALGIMIGLI, MD
Discover more about Xience
AP2944533-WBO Rev. H